UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): March 31, 2006
VioQuest
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-16686
|
58-1486040
|
|
(State
or other jurisdiction of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification
No.)
|
180
Mount Airy Road, Suite 203
Basking
Ridge, New Jersey 07920
(Address
of principal executive offices)
(908)
766-4400
(Registrant's
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
1.01 Entry
into a Material Definitive Agreement
On
March 31, 2006, the Board of Directors of VioQuest Pharmaceuticals, Inc. (the
“Company”) approved grants of stock options to Michael Cannarsa,
General Manager of the Company’s Chiral Quest, Inc. subsidiary, for 50,000
shares; Yaping Hong, Senior Vice President of Global Process Research and Development,
for 75,000 shares; Brian Lenz, Chief Financial Officer, for 100,000 shares;
and Richard Welter, Vice President of Corporate Business Development for 100,000
shares. The options will vest in three annual equal installments beginning March
31, 2007. Options were also approved for Johnson Y. N. Lau, a director of the
Company for 150,000 shares; 75,000 of which vest immediately and the remainder
on March 31, 2007. The exercise price for all of the foregoing options is $0.85,
the closing price of the Company’s common stock on March 31, 2006. All
of the foregoing options were issued under the Company’s 2003 Stock Option
Plan.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
VioQuest
Pharmaceuticals, Inc.
|
|
|
|
| Date: April
6, 2006 |
By: |
/s/ Brian
Lenz |
| |
Brian Lenz
|
| |
|